Barba-Vila Olga, García-Mieres Helena, Ramos Belén
Department de Bioquímica i Biología Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona Bellaterra, Barcelona, Spain.
Etiopathogenesis and Treatment of Severe Mental Disorders, Teaching, Research, and Innovation Unit, Institut de Recerca Sant Joan de Déu, Parc Sanitari Sant Joan de Déu Sant Boi de Llobregat, Barcelona, Spain.
Nutr Rev. 2025 Feb 1;83(2):329-343. doi: 10.1093/nutrit/nuae010.
It is hypothesized that gut dysbiosis, a typical feature of patients with autism spectrum disorder (ASD), could be involved in the origin of this neurodevelopmental disorder. Therefore, the use of probiotics to restore gastrointestinal (GI) equilibrium might be a promising therapeutic strategy due to its capacity to balance the gut-brain axis and behavioral responses.
To summarize current knowledge on the use of probiotics to treat core clinical ASD symptoms and concomitant GI signs, compare the design of published studies with those of ongoing trials, assess the near future of this field, and provide recommendations for improving novel studies.
The literature search was conducted in February 2020 and updated in March 2021, using a broad range of bibliographic and clinical trial-specific databases.
Data were extracted using a standardized form, and articles reporting on 28 clinical studies (already published or still ongoing) were included. The risk of bias in clinical studies was evaluated using the Cochrane Collaboration Risk of Bias Assessment tool for randomized trials and the Risk of Bias in Nonrandomized Studies-Interventions tool for nonrandomized trials.
The results suggest that probiotics improve ASD-like social deficits, GI symptoms, and gut microbiota profile. However, inconsistencies among studies and their methodological limitations make it difficult to draw any conclusions regarding the efficacy of probiotics in ASD. This review provides specific suggestions for future research to improve the quality of the studies.
Although ongoing studies have improved designs, the available knowledge does not permit solid conclusions to be made regarding the efficacy of probiotics in ameliorating the symptoms (psychiatric and/or GI) associated with ASD. Thus, more high-quality research and new approaches are needed to design effective probiotic strategies for ASD.
据推测,肠道菌群失调作为自闭症谱系障碍(ASD)患者的一个典型特征,可能与这种神经发育障碍的起源有关。因此,使用益生菌来恢复胃肠道(GI)平衡可能是一种有前景的治疗策略,因为它有能力平衡肠道-脑轴及行为反应。
总结目前关于使用益生菌治疗ASD核心临床症状及伴随的胃肠道体征的知识,将已发表研究的设计与正在进行的试验的设计进行比较,评估该领域的近期前景,并为改进新研究提供建议。
2020年2月进行文献检索,并于2021年3月更新,使用了广泛的书目数据库和特定临床试验数据库。
使用标准化表格提取数据,纳入了报告28项临床研究(已发表或仍在进行)的文章。使用Cochrane协作网随机试验偏倚风险评估工具和非随机研究-干预偏倚风险工具评估临床研究中的偏倚风险。
结果表明,益生菌可改善ASD样社交缺陷、胃肠道症状和肠道微生物群谱。然而,研究之间的不一致及其方法学局限性使得难以就益生菌在ASD中的疗效得出任何结论。本综述为未来研究提供了具体建议,以提高研究质量。
尽管正在进行的研究改进了设计,但现有知识仍无法就益生菌改善与ASD相关症状(精神和/或胃肠道)的疗效得出确凿结论。因此,需要更多高质量的研究和新方法来设计有效的ASD益生菌策略。